Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases

Refractory aggressive prolactinomas are detected after the unresponsiveness to conventional therapies. We report two cases that underwent temozolomide treatment and have been in near‐complete remission ever since. We suggest the pathology techniques for earlier detection and, subsequently, treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Davoudi, Zahra, Hallajnejad, Mohammad, Jamali, Elena, Honarvar, Mohammadjavad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291256/
https://www.ncbi.nlm.nih.gov/pubmed/35865778
http://dx.doi.org/10.1002/ccr3.6087
_version_ 1784749101589463040
author Davoudi, Zahra
Hallajnejad, Mohammad
Jamali, Elena
Honarvar, Mohammadjavad
author_facet Davoudi, Zahra
Hallajnejad, Mohammad
Jamali, Elena
Honarvar, Mohammadjavad
author_sort Davoudi, Zahra
collection PubMed
description Refractory aggressive prolactinomas are detected after the unresponsiveness to conventional therapies. We report two cases that underwent temozolomide treatment and have been in near‐complete remission ever since. We suggest the pathology techniques for earlier detection and, subsequently, treatment with temozolomide to reduce morbidities and better respond to therapy.
format Online
Article
Text
id pubmed-9291256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92912562022-07-20 Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases Davoudi, Zahra Hallajnejad, Mohammad Jamali, Elena Honarvar, Mohammadjavad Clin Case Rep Case Report Refractory aggressive prolactinomas are detected after the unresponsiveness to conventional therapies. We report two cases that underwent temozolomide treatment and have been in near‐complete remission ever since. We suggest the pathology techniques for earlier detection and, subsequently, treatment with temozolomide to reduce morbidities and better respond to therapy. John Wiley and Sons Inc. 2022-07-18 /pmc/articles/PMC9291256/ /pubmed/35865778 http://dx.doi.org/10.1002/ccr3.6087 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Davoudi, Zahra
Hallajnejad, Mohammad
Jamali, Elena
Honarvar, Mohammadjavad
Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
title Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
title_full Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
title_fullStr Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
title_full_unstemmed Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
title_short Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
title_sort aggressive prolactinomas responsive to temozolomide treatment: report of two cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291256/
https://www.ncbi.nlm.nih.gov/pubmed/35865778
http://dx.doi.org/10.1002/ccr3.6087
work_keys_str_mv AT davoudizahra aggressiveprolactinomasresponsivetotemozolomidetreatmentreportoftwocases
AT hallajnejadmohammad aggressiveprolactinomasresponsivetotemozolomidetreatmentreportoftwocases
AT jamalielena aggressiveprolactinomasresponsivetotemozolomidetreatmentreportoftwocases
AT honarvarmohammadjavad aggressiveprolactinomasresponsivetotemozolomidetreatmentreportoftwocases

Ejemplares similares